

1 CONTRACT Study - CONservative TRreatment of Appendicitis in Children (feasibility): study
2 protocol for a randomised controlled Trial

3 Hutchings, Natalie¹ (n.j.hutchings@soton.ac.uk); Wood, Wendy² (W.Wood@soton.ac.uk); Reading,
4 Isabel³ (i.c.reading@soton.ac.uk); Walker, Erin⁴ (Erin.Walker@gosh.nhs.uk); Blazeby, Jane⁵
5 (J.M.Blazeby@bristol.ac.uk); Van't Hoff, William⁴ (William.Van'tHoff@gosh.nhs.uk); Young, Bridget⁶
6 (Bridget.Young@liverpool.ac.uk); Crawley, Esther⁷ (Esther.Crawley@bristol.ac.uk); Eaton, Simon⁸
7 (s.eaton@ucl.ac.uk); Chorozoglou, Maria⁹ (M.Chorozoglou@soton.ac.uk); Sherratt Frances C⁶
8 (Frances.Sherratt@liverpool.ac.uk); Beasant, Lucy⁷ (Lucy.Beasant@bristol.ac.uk); Corbett, Harriet¹⁰
9 (Harriet.Corbett@alderhey.nhs.uk); Stanton, Michael¹¹ (Michael.Stanton@uhs.nhs.uk); Grist, Simon¹²
10 (contract@soton.ac.uk); Dixon, Elizabeth¹ (E.Dixon@soton.ac.uk); Hall, Nigel J^{11,13}
11 (n.j.hall@soton.ac.uk)

- 12 1. Southampton Clinical Trials Unit, Faculty of Medicine, University of Southampton
- 13 2. National Institute of Health Research (NIHR), Research Design Service South Central,
14 University of Southampton
- 15 3. Primary Care and Population Sciences, Faculty of Medicine, University of Southampton
- 16 4. Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
17 (UK)
- 18 5. Centre for Surgical Research, Population Health Sciences, Bristol Medical School, University
19 of Bristol
- 20 6. Institute of Psychology, Health & Society, University of Liverpool
- 21 7. Centre for Child and Adolescent Health, School of Social and Community Medicine,
22 University of Bristol
- 23 8. UCL Great Ormond Street Institute of Child Health
- 24 9. Southampton Health Technology Assessment Centre, Faculty of Medicine, University of
25 Southampton

26 10. Department of Paediatric Surgery, Alder Hey Children's NHS foundation Trust, East Prescott
27 Road, Liverpool, L14 5AB

28 11. Department of Paediatric Surgery and Urology, Southampton Children's Hospital, University
29 Hospital Southampton NHS Foundation Trust, UK

30 12. Patient and Public Involvement Representative

31 13. University Surgery Unit, Faculty of Medicine, University of Southampton

32 Author for correspondence:

33 Nigel Hall

34 University Surgery Unit, Faculty of Medicine

35 Mailpoint 816, University of Southampton

36 Tremona Road, Southampton SO16 6YD

37 Email: n.j.hall@soton.ac.uk

38 [Abstract](#)

39 Currently, the routine treatment for acute appendicitis in the UK is an appendicectomy. However,
40 there is increasing scientific interest and research into non-operative treatment of appendicitis in
41 adults and children. While a number of studies have investigated non-operative treatment of
42 appendicitis in adults, this research cannot be applied to the paediatric population. Ultimately we aim
43 to perform a UK based multicentre randomised controlled trial (RCT), to test clinical and cost
44 effectiveness of non-operative treatment of acute uncomplicated appendicitis in children compared
45 to appendicectomy. First, we will undertake a feasibility study to assess the feasibility of performing
46 such a trial.

47 [Methods:](#)

48 The study involves a feasibility RCT with nested qualitative research to optimise recruitment and a
49 health economic sub-study. Children (aged 4-15 inclusive) diagnosed with acute uncomplicated
50 appendicitis that would normally be treated with an appendicectomy are eligible for the RCT.

51 Exclusion criteria include clinical/radiological suspicion of perforated appendicitis, appendix mass or
52 previous non-operative treatment of appendicitis. Participants will be randomised into one of two
53 arms. The intervention arm is treated with antibiotics and regularly clinical assessment to ensure
54 clinical improvement. The control arm will receive appendicectomy. Randomisation will be minimised
55 by age, gender, duration of symptoms and centre. Children and families who are approached for the
56 RCT will be invited to participate in the embedded qualitative sub-study which includes recording of
57 recruitment consultants and subsequent interviews with participants and non-participants and their
58 families, and recruiters. Analyses of these will inform interventions to optimise recruitment. Main
59 study outcomes include recruitment rate (primary outcome), identification of strategies to optimise
60 recruitment, performance of trial treatment pathways, clinical outcomes and safety of non-operative
61 treatment. We have involved children, young people and parents in study design and delivery.

62 Discussion:

63 This study will explore the feasibility of performing a full, efficacy RCT comparing non-operative
64 treatment with appendicectomy in children with acute uncomplicated appendicitis. Factors
65 determining success of the current study include recruitment rate, safety of non-operative treatment,
66 and adequate interest in the future RCT. Ultimately this feasibility study will form the foundation of
67 the main RCT and reinforce its design.

68 Registration:

69 ISRCTN, ISRCTN15830435. Registered 8 February 2017, <http://www.isrctn.com/ISRCTN15830435>

70 Keywords:

71 Appendicitis, non-operative treatment, paediatric surgery, appendicectomy, feasibility

72 Background

73 Acute appendicitis is the most common surgical emergency in children [1]. The lifetime risk of
74 developing appendicitis is 7-8% and the most common age for developing appendicitis is in the early
75 teens. Appendicectomy is considered the gold standard treatment for acute appendicitis by most

76 surgeons but many parents and patients find the prospect that their child needs emergency surgery
77 frightening and one they are keen to avoid if an alternative is available [2]. Preliminary work we have
78 already undertaken with children and families confirms a high level of interest in non-operative
79 treatment and indeed a preference for non-operative treatment so long as clinical outcomes are
80 comparable.

81 Although appendicectomy is considered a simple procedure, it requires a general anaesthetic and an
82 abdominal operation with its associated risks. The complication rate of appendicectomy (including
83 wound infection, intra-abdominal abscess, and adhesional small bowel obstruction) is up to 25% [3]
84 with a need for hospital readmission in 4-5% of cases [4, 5]. A contemporary estimation of these risks
85 is available from the National Appendicectomy Audit, a nationwide audit of outcomes of
86 appendicectomy for acute appendicitis in 19 Specialist Paediatric Surgery Centres in the UK [6]. Over
87 a 2 month period, 242 appendicectomies for acute appendicitis were performed. The negative
88 (histologically normal) appendicectomy rate was 10.3% and the 30-day adverse event (AE) rate (a
89 composite of readmission, re-intervention, pelvic collection and wound infection) was 15.3%.

90 The economic burden to the healthcare system of paediatric appendicitis in England is in excess of £21
91 million per year and requires significant resource use including need for out-of-hours surgery (45% of
92 all paediatric appendicectomies were performed between 1800 and 0800 in the National
93 Appendicectomy Audit).

94 An alternative approach to treating acute appendicitis in children would be treatment with antibiotics
95 and without an appendicectomy. Whilst there is growing scientific interest in the use of non-operative
96 treatment with antibiotics due to its potential benefits over surgery and existing data to support its
97 safety, the relative efficacy of this approach compared to appendicectomy is not yet known [7]. Using
98 a non-operative approach to treat appendicitis, patients may avoid the mental and physical stress and
99 trauma of an operation as well as the associated complications. Non-operative treatment has the
100 potential to reduce the quantity of resources used by the National Health Service (NHS). For example,

101 by reducing the amount of theatre time, staff time and surgical resources used for the treatment of
102 appendicitis, there could be significant savings for the NHS.

103 It has been known for some time that acute appendicitis can be treated successfully by antibiotics
104 alone, in the context of remote environments without surgical service capability [8]. However, the role
105 of non-operative treatment as primary therapy has only recently come under consideration in
106 developed healthcare systems, initially in adults [3, 9-15], and more recently in children [16-18].
107 Although studies in adults are sometimes extrapolated to children, to do so is problematic since there
108 are key differences in appendicitis occurring in adults compared to children. The presentation of
109 appendicitis and the intra-abdominal inflammatory response is different in adults and children [19,
110 20] and may be more amenable to antibiotic treatment alone, and the psychosocial and economic
111 impact of appendicitis in children affects the whole family, rather than just the individual. Therefore,
112 a paediatric RCT is necessary to compare both treatment options.

113 There is just one pilot RCT, recently performed in Sweden, comparing non-operative treatment with
114 antibiotics with appendicectomy in children with acute appendicitis [18]. Fifty children (aged 5-15
115 years) with acute non-perforated appendicitis were randomised to antibiotics (n=24) or
116 appendicectomy (n=26). All children in the surgery group had histopathologically-confirmed acute
117 appendicitis and none experienced a significant surgical complication. In the antibiotic group, 2 of 24
118 underwent appendicectomy within the time of primary antibiotic treatment, and 1 further child
119 required appendicectomy for histologically-proven, recurrent acute appendicitis 9 months later. Of
120 eligible participants, the recruitment rate was 40%, the drop-out rate following treatment allocation
121 was 2% (1 patient) and no patient was lost to follow-up by 1 year. This pilot study was not powered
122 sufficiently to compare the efficacy of antibiotics versus surgery, but was conducted to inform the
123 design of an international, multicentre RCT which is currently recruiting in non-UK centres [21].

124 Our group have recently performed a systematic review and meta-analysis comparing the efficacy of
125 non-operative treatment and appendicectomy for uncomplicated appendicitis in children [7]. Whilst

126 there were limitations related to a lack of RCTs, the existing data support a position of equipoise
127 between these two treatment approaches. Neither this review nor any of the contributing studies [16-
128 18, 22-24] identified any safety concerns regarding non-operative treatment.

129 In addition to outcomes of the acute illness, the development of recurrent appendicitis is an important
130 consideration in children who receive non-operative treatment that is not applicable to children
131 treated with appendicectomy. In adults [9-12, 25] the incidence of recurrence (within 1 year) is around
132 15%. A recent pilot study of non-operative treatment of appendicitis in children with 1 year follow-up
133 reported a recurrence rate of 5% [18] and our recent systematic review estimated an incidence of 14%
134 [7]. This is the best current estimate in children.

135 Given the current uncertainty, regarding the relative efficacy and cost-effectiveness of non-operative
136 treatment compared to appendicectomy in children with uncomplicated acute appendicitis, a
137 definitive RCT is necessary. Although RCTs are ongoing in other countries [26, 27] there are important
138 differences in diagnostic techniques and healthcare delivery in the UK that mandate a UK specific trial.
139 These include a much lower reliance on diagnostic imaging for confirmation of appendicitis in the UK
140 compared to other countries, a higher negative appendicectomy rate and a lower uptake of
141 laparoscopic appendicectomy in the UK, all of which may influence relative efficacy of non-operative
142 treatment compared to surgery [6, 28]. Prior to performing a large efficacy trial, we designed this
143 feasibility study, which includes a feasibility RCT, to inform the design and conduct of a future RCT and
144 establish whether a main trial is possible in the UK.

145 [Methods/Design](#)

146 [Study Design:](#)

147 The CONTRACT study comprises:

- 148 1. A randomised controlled feasibility trial of children comparing a non-operative treatment pathway
149 with appendicectomy. A standardised treatment pathway (Figure 1) will be used in each arm of
150 the study beginning with broad-spectrum antibiotics from the point of enrolment. One arm will

151 then undergo urgent appendicectomy while the other will be treated non-operatively with
152 continuation of broad-spectrum antibiotics. Both treatment pathways will receive the same follow
153 up schedule.

154 2. A detailed programme of embedded qualitative and quantitative research to optimise recruitment
155 to the feasibility RCT. It will also inform the design and conduct of any future RCT of non-operative
156 treatment versus appendicectomy in the treatment of acute uncomplicated appendicitis in
157 children.

158 3. A health economics (HE) feasibility study to allow the identification of key cost drivers and other
159 parameters necessary to perform a full economic evaluation in our future RCT. This will include
160 the design and piloting of data collection tools and adoption of a micro-costing approach. A full
161 protocol of the HE sub-study is described separately.

162 4. The development of a Core Outcome Set (COS) for the non-operative treatment of children with
163 uncomplicated acute appendicitis for use in the future RCT as well as the wider research
164 community. A full protocol for the COS is published elsewhere [29].

165 5. A patient and public involvement (PPI) work stream that reciprocally feeds into elements 1, 2 and
166 4 (above). We have formed a Study Specific Advisory Group (SSAG) made up of children who have
167 had acute uncomplicated appendicitis, children who have not, and parents.

168 [1. Randomised Controlled Feasibility Trial](#)

169 [Population:](#)

170 Children aged 4-15 inclusive, with a clinical diagnosis of acute appendicitis who would normally be
171 treated with an appendicectomy as part of their standard care. Patients will be identified by the clinical
172 team at the time of diagnosis and their eligibility will be confirmed by the research team as soon as
173 possible.

174 [Inclusion criteria:](#)

- 175 • Children age 4 – 15 years (>3 and <16 years)

176 • Clinical diagnosis, either with or without radiological assessment, of acute appendicitis which
177 prior to study commencement would be treated with appendicectomy

178 • Written informed parental consent, with child assent if appropriate

179 Exclusion criteria:

180 • Clinical signs or radiological findings to suggest perforated appendicitis

181 • Presentation with appendix mass

182 • Previous episode of appendicitis or appendix mass treated non-operatively

183 • Major anaesthetic risk precluding allocation to the appendicectomy arm

184 • Known antibiotic allergy preventing allocation to non-operative treatment arm

185 • Antibiotic treatment started at referring institution (defined as 2 or more doses administered)

186 • Cystic fibrosis

187 • Positive pregnancy test

188 • Current treatment for malignancy

189 Randomisation:

190 Eligible patients will be identified, approached and consented by the treating clinician. After written
191 informed consent, a member of the trial team at site will randomised the participant to one of two
192 treatment groups in a 1:1 ratio via an independent web-based system (TENALEA). This online system
193 allows complete pre-randomisation concealment of treatment allocation and provides instant
194 assignment to either the Appendicectomy or Non-Operative treatment group. Minimisation will be
195 used to account for recruiting centre and ensure balance between the groups in factors that may
196 affect diagnostic accuracy and outcome of treatment. The factors which are taken into account are a)
197 Gender: Male; Female, b) Age: 4-8; 9-15, c) Duration of symptoms (onset of pain to recruitment into
198 study): <48 hours; ≥48 hours, and d) Recruiting centre.

199 [Interventions](#)

200 **Figure 1: Clinical pathway for both treatment arms.**

201 [Non-operative treatment group:](#)

202 This treatment pathway will comprise fluid resuscitation, minimum of 24 hours broad spectrum
203 Intravenous (IV) antibiotics (per local policies), minimum of 12 hours nil by mouth (NBM) and regular
204 clinical review to detect signs and symptoms of significant clinical deterioration including, but not
205 limited to, increasing fever, increasing tachycardia, and increasing tenderness. After the initial 12-hour
206 period of NBM, oral intake will be advanced as tolerated. Children successfully treated without an
207 operation, will be converted to oral antibiotics once they are afebrile for 24 hours and tolerating oral
208 intake (per local policies and after the minimum 24 hours IV).

209 Clinical reviews will also be completed at approximately 24 and 48 hours post randomisation. Any
210 children who show signs of significant clinical deterioration by 24 hours, or at any point during the
211 trial, will undergo appendicectomy. Children who are considered stable or improving will continue
212 with non-operative treatment. At 48 hours, any children who have not shown clinical improvement
213 will also undergo appendicectomy. The decision to continue non-operative treatment at these time
214 points or to recommend discontinuation of non-operative treatment and appendicectomy, will be
215 made by the treating consultant and based on clinical judgement rather than any specific features that
216 are not evidence based. All reasons for change in treatment will be recorded in detail.

217 Any children who receive an appendicectomy for an incomplete response to non-operative treatment,
218 will follow a standardised post-operative treatment regime already in use at each institution and
219 identical to that used in the appendicectomy arm. The reason for having an appendicectomy will be
220 recorded.

221 [Appendicectomy group:](#)

222 Children randomised to the appendicectomy arm will undergo either open or laparoscopic
223 appendicectomy at the surgeon's discretion, performed by a suitably experienced trainee (as per

224 routine current practice) or a consultant. A peritoneal microbiology swab will be taken at the time the
225 peritoneum is first opened or from the appendix, and any peritoneal fluid sent for microbiological
226 culture. The results of this swab will be recorded.

227 Patients will receive IV antibiotics from the time of randomisation and be treated post-operatively
228 with IV antibiotics according to existing institutional protocols, however the following recommended
229 regime is used to guide practice: children with acute uncomplicated appendicitis or a macroscopically
230 normal appendix will receive no further antibiotics. Children with a perforated appendix (defined as a
231 faecolith or faecal matter within the peritoneal cavity, or visualisation of a hole in the appendix) will
232 continue to receive IV antibiotics for a minimum of 3 days, and will receive a minimum total course of
233 antibiotics of 5 days (IV and oral). It is not possible to standardise the duration of antibiotics therapy
234 due to anticipated variation in intra-operative findings and in response to treatment. The type of
235 antibiotics used will be identical to those used in the non-operative treatment arm within each centre.
236 Any child failing to respond to these first line antibiotics will be treated as is clinically appropriate with
237 a longer course of antibiotics or a change in antibiotic therapy with the choice of antibiotic determined
238 by intra-operative swab or fluid culture.

239 Post-operatively, children with uncomplicated acute appendicitis or a normal appendix will not
240 routinely have a nasogastric tube, nor a urinary catheter. They will receive oral intake as tolerated
241 after surgery.

242 [Discharge Assessment:](#)

243 Criteria for discharge home will be identical to those in both treatment groups and will be: vital signs
244 within normal limits for age, afebrile for ≥ 24 hours, tolerating light diet orally, adequate oral pain relief
245 and be mobile. Patients will receive a total course of 10 days antibiotics following randomisation,
246 unless decided otherwise by the clinician. If more than 10 days oral antibiotics are administered, this
247 will be recorded (including reason). Children who receive non-operative treatment will not be

248 routinely offered interval appendicectomy but will be counselled about the risk of recurrence using
249 best available data.

250 Once a decision to discharge the child has been made, a member of the clinical team who has not
251 been directly involved in the child's treatment will be asked to complete a discharge assessment. This
252 assessor will not have prior knowledge of the randomisation or treatment received by the child. Upon
253 completion of the discharge assessment, they will "guess" which treatment the child received. If the
254 assessor should become unblinded during the assessment, this will also be recorded. Through this we
255 hope to be able to determine the feasibility of a blinded discharge assessment in a future RCT.

256 *Follow up:*

257 Follow-up appointments for all participants will take place at 6 weeks, 3 and 6 months following
258 discharge, either in the outpatient clinic or the Clinical Research Facility at each centre. If a face-to-
259 face appointment is not possible, the 3 and 6 month follow up can be completed over the phone. Data
260 on resource use, time to return to daily activities and recurrent appendix-related problems (including
261 unexplained abdominal pain and recurrence) will be collected prospectively to ensure high accuracy.
262 The schedule of enrolment, intervention and follow up can be found in figure2.

263 **Figure 2: Patient schedule of procedures (SPIRIT).**

264 *Primary outcome:*

265 The primary outcome is to assess whether it is feasible to conduct a multi-centre RCT testing the
266 effectiveness and cost-effectiveness of a non-operative treatment pathway for the treatment of acute
267 uncomplicated appendicitis in children. This will be evaluated as the proportion of eligible patients
268 who are approached and recruited to the study over 12 months.

269 *Secondary outcomes:*

270 The secondary outcomes are predominately centred on the qualitative and COS sub studies
271 contributing towards the development of a future RCT.

- 272 1. Willingness of parents, children and surgeons to take part in a randomised study comparing
273 operative versus non-operative treatment and identify anticipated recruitment rate. This will
274 be assessed from audio recorded family-surgeon recruitment consultations, interviews with
275 patients, parents, surgeons and nurses, surgeon surveys and focus groups.
- 276 2. Identification of strategies to optimise surgeon-family communication using the above
277 consultation and interview data.
- 278 3. Design of a future RCT from the perspectives of stakeholders at participating sites (children,
279 parents, surgeons, nurses etc.) informed by the consultation and interview data, surgeon
280 surveys and focus groups.
- 281 4. Assessment of the equipoise and willingness of UK paediatric surgeons to participate in a
282 future RCT through surgeon surveys and focus groups.
- 283 5. Clinical outcomes of trial treatment pathways including (i) overall success of initial non-
284 operative treatment (measured as the number of patients randomised to non-operative
285 treatment, discharged from hospital without appendicectomy); (ii) complications of disease
286 and treatment (measured during hospital stay and 6 month follow-up period); (iii) rate of
287 recurrent appendicitis during 6 month follow-up period.
- 288 6. Performance of study procedures including retention of participants for the duration of the
289 study, and feasibility of outcome recording and data collection systems.

290 [Sample Size Calculations:](#)

291 The study will recruit participants from 3 centres for 12 months. Each centre treats 80-100 children
292 per year with acute appendicitis, with an estimate that at least 130 will be eligible out of the 240-300
293 potential patients. Assuming 40-50% will be recruited (i.e. 52-65 participants in feasibility RCT) we will
294 be able to estimate a true 40% recruitment rate with a 95% confidence interval (CI) of 31% to 49% and
295 a true 50% recruitment rate with a 95% CI of 41% to 59%. 52-65 participants in the feasibility RCT will
296 be adequate to test treatment pathway procedures, data collection methods and loss to follow-up.

297 For the embedded qualitative work related to recruitment, we will recruit until we reach data
298 saturation which we estimate will entail analysing approximately 40 recruitment consultations, 20-30
299 family interviews, and 20-25 healthcare professional interviews.

300 *Clinical trial data analysis:*

301 Data analysis will be performed by the study statistician who will be blinded to treatment allocation
302 by the use of coded data, as per the statistical analysis plan. As this is a feasibility study, all analyses
303 will be treated as preliminary and exploratory and will be mainly descriptive. Feasibility outcomes
304 (number of eligible patients, recruitment/retention rates, reasons for non-participation, success of
305 blinding of the discharge assessor), treatment outcomes and complications will be presented by
306 simple summary statistics with 95% confidence intervals. Clinical outcome measures will be compared
307 between treatment groups in an exploratory analysis, and variability estimates will be used to inform
308 the sample size for a future definitive trial. The study will be reported in accordance with the CONSORT
309 2010 statement.

310 *Trial Oversight and Safety Monitoring:*

311 A Study Management Group (SMG) will be responsible for overseeing the day-to-day management of
312 the trial. A Trial Steering Committee (TSC) and Data Monitoring and Safety Committee (DMSC) will
313 also share independent oversight of the study. The DMSC will review the trial and its data from a safety
314 and ethical perspective and will make recommendations regarding the continuation of the trial to the
315 TSC who will make the ultimate decision. The roles and responsibilities of each committee is detailed
316 in a separate charter. The SMG will feed back to the SSAG, and vice versa.

317 Any patient who does not complete the non-operative treatment pathway within the trial (i.e.
318 deteriorates or does not improve) and undergoes appendicectomy will be reported to the Trial
319 Manager (TM) within 48 hours of appendicectomy. The TM will inform the TSC chairperson and convey
320 the clinical data relating to this patient. The TSC chair will hold responsibility for determining whether
321 to ask the DMSC to meet and review the data from that patient. The DMSC will subsequently advise

322 the TSC on their findings including an assessment of whether it is acceptable to continue to recruit
323 patients.

324 [2. Qualitative Sub Study:](#)

325 The embedded qualitative sub-study comprises audio recordings of recruitment consultations
326 between patients, their families and recruiters (paediatric surgeons and research nurses), and follow
327 up interviews with patients, their families and recruiters about their experiences of recruitment and
328 the trial. Focus groups will also be conducted with paediatric surgeons at non-study sites about their
329 views of the trial. When patients are approached about the study, they will be asked for verbal consent
330 to audio record the discussion. Seeking written consent for the audio recording at this point would
331 distract from the focus of the consultation, therefore we will ask patients at the end of the
332 consultation for written consent to keep the recording and use it for analysis. After discharge a trained
333 qualitative researcher will contact and invite patients and families to be interviewed either in their
334 homes or by telephone. Recruiters will also be invited to be interviewed either in their place of work
335 or by telephone. All consultations and interviews will be digitally audio-recorded and uploaded for
336 transcription by a professional transcription service and pseudo anonymised before analysis.

337 [Analysis of recruitment consultations:](#)

338 Analyses of the recruitment consultations will use both the recordings and transcripts to document
339 the interactions between recruiters and families, explore information provision, use of
340 communication techniques as well as intervention preferences and trial participation decisions. If
341 analyses of the audio-recordings suggest that recruitment difficulties are potentially linked to
342 communication during the recruitment consultation, this will be fed back to the local PIs so training of
343 recruiters can be implemented immediately. The equipoise and views of health care professionals
344 recruiting to the trial will also be assessed, as well as the key ways in which their views differ from
345 non-participating surgeons.

346 The analyses will also draw upon content analytic methods to describe what was said by whom and
347 how often in the audio-recordings of recruitment sessions. Constant comparison methods will also
348 inform identification of common or divergent themes, particularly focusing on the impact of
349 statements by the recruiter on parent responses and views. This will focus on key sections of the
350 transcripts, for example, when randomisation is offered. The percentage of eligible patients recruited
351 will be documented using site screening logs, noting any families who decline randomisation or do not
352 accept the randomised allocation.

353 *[Analysis of interview and focus group data:](#)*

354 The findings from the analysis of the recruitment consultations will be linked with qualitative data
355 from the interviews where patients discuss the acceptability of trial methodology to determine the
356 feasibility and acceptability of a full trial, and also with the recruiter interviews. Analysis of interview
357 and focus group data will draw on the principles of the constant comparative method and thematic
358 analysis. One member of the research team will lead a process of 'cycling' between the developing
359 analysis and new data. Other members of the qualitative study team (including at least one surgeon)
360 will develop and test the analysis by periodic discussion and independent analyses of a proportion of
361 transcripts to compare coding and findings.

362 Initially, each transcript will be read several times by the lead analyst, before developing open codes
363 to describe each relevant unit of meaning, although coding will occur at multiple levels, from detailed
364 descriptions of communication and experiences of the trial, to the general orientation of participants
365 towards clinical research. Through comparison within and across the transcripts, the open codes will
366 be developed into categories to reflect and test the developing analysis. The categories will be
367 organised into a framework to code and index the transcripts using QSR NVivo software. The
368 framework categories will be continually checked and modified to ensure an adequate 'fit' with the
369 data, whilst also accounting for variation in the data and 'deviant' cases. A second member of the

370 team will check the categories and the assignment of data to them. Our analytic approach will be
371 informed by writings on quality in qualitative research [30].

372 5. [Patient and Public Involvement](#)

373 We recognise that PPI is a crucial element for this study, and as such, will form a SSAG made up of
374 parents, children and young people; some of which will have experience of treatment for acute,
375 uncomplicated appendicitis. This group will provide overarching consultation and collaboration
376 functions for the programme of research, minus the HE sub-study. The group will help devise patient
377 and parent documentation (including but not limited to, information sheets, consent forms, and a
378 recruitment video), provide insight on the qualitative sub-study interview schedule and COS
379 development. They will also help with the dissemination of the results; back to study participants, via
380 information sources accessed by children, young people and parents, and through a variety of media.

381 Discussion

382 [Progression to main trial:](#)

383 Through this initial study we aim to inform the design, conduct and feasibility of a future efficacy RCT
384 whilst confirming the safety of non-operative treatment in UK paediatric surgical centres for the first
385 time. The decision to progress to a future RCT will be based on a combination of recruitment rate
386 achieved, safety of non-operative treatment and adequate surgeon interest. These issues will be
387 discussed by the trial management and oversight groups and be reviewed by a new funding panel.
388 Currently we think that a future main RCT will be considered feasible if:

- 389 1. The lower boundary of the 95% CI of the recruitment rate is above 20%. Whilst it is likely there
390 are adequate patients to complete a study in which the recruitment rate is less than 20%, this
391 is interpreted as lack of patient interest in non-operative treatment or potentially concerns
392 about the trial and associated treatment.
- 393 2. The DMSC do not stop the trial on safety grounds. If the DMSC choose to stop the trial, the
394 non-operative treatment pathway will have to be reconsidered before a future RCT is planned.

395 3. Adequate surgeons and centres can be identified are required to achieve target recruitment.
396 Based on the current sample size estimate, 5-10 UK Paediatric Surgery Centres are required
397 to make a future RCT feasible.

398 *Specific Ethical Considerations:*

399 1. Participants will be randomised to a novel care pathway, which although in use at a
400 number of institutions worldwide, has not been rigorously tested to assess efficacy and
401 safety in participating centres. Although existing literature proposes that the non-
402 operative pathway is safe [7, 16, 24], patients and their families will be informed that the
403 clinical outcomes are being investigated as part of the study. Clinical reviews have been
404 incorporated into the treatment pathways to minimise risk and/or complications of
405 unsuccessful treatment.

406 2. Although written informed consent will be given by the parent or guardian, the child will
407 be given age appropriate information about the study and may confirm their assent during
408 the completion of the consent form if they wish to do so. Consent will be taken by a
409 member of the surgical team who has experience recruiting children to research and
410 completed appropriate Good Clinical Practice training. A copy of the study consent form
411 is included with the study protocol [see additional file 1]

412 3. Due to the urgency associated with the treatment of appendicitis, the period for taking
413 consent will be short to ensure that the research process does not impede upon the
414 provision of safe and effective care but does allow sufficient time for patients and their
415 family to make an informed decision about the trial.

416 Some patients/parents may be concerned that delay in appendicectomy may increase the rate of
417 perforation and AEs. However this is not borne out by the literature on large numbers of adult [31]
418 and paediatric patients [31-35] and participants will be counselled accordingly.

419 Following treatment children in the non-operative treatment group will theoretically continue to be
420 at risk of recurrence of appendicitis. Whilst the risk of recurrence is low, the child and their families
421 will be fully informed of this risk. We will seek permission from these families to hold their personal
422 details in a secured registry and to contact them in the future to determine if they have had a
423 recurrence.

424 [Trial Status](#)

425 Protocol version 2, 10th April 2017. The study opened to recruitment on the 1st March 2017 and will
426 recruit patients for a period of 12 months until 28th February 2018 at 3 paediatric surgical teaching
427 hospitals in England; Alder Hey Children’s Hospital, Liverpool, Southampton General and St George’s
428 Hospital, London.

429 [List of Abbreviations](#)

430	AE	Adverse Event
431	CI	Confidence Interval
432	COS	Core Outcome Set
433	DMSC	Data Monitoring and Safety Committee
434	HE	Health Economics
435	IV	Intravenous
436	NBM	Nil By Mouth
437	NIHR	National Institute of Health Research
438	NHS	National Health Service
439	PPI	Patient and Public Involvement
440	RCT	Randomised Controlled Trial
441	SMG	Study Management Group
442	SSAG	Study Specific Advisory Group
443	TM	Trial Manager

444 TSC Trial Steering Committee

445 UK United Kingdom

446 [Declarations](#)

447 [Ethics approval and consent to participate:](#)

448 Approval for this study was granted by the South Central – Hampshire A Research Ethics Committee
449 (16/SC/0596) and written informed consent will be obtained from the parents/guardians of the
450 patients before any trial procedures are completed. There is also the option for the patients to confirm
451 their assent during the completion of the consent form.

452 [Consent for publication:](#)

453 Not applicable

454 [Availability of data and material:](#)

455 Not applicable

456 [Competing interests:](#)

457 Professor Jane Blazeby is a NIHR Senior Investigator.

458 The remaining authors report no competing interests.

459 [Funding:](#)

460 The authors acknowledge funding from the UK National Institute for Health Research Health
461 Technology Assessment Board (14/192/90), the National Institute for Health Research Clinical
462 Research Network and support from the NIHR Clinical Research Network.

463 SE acknowledges support from Great Ormond Street Children’s Charity and from the NIHR Great
464 Ormond Street Biomedical Research Centre.

465 LB is funded by the Medical Research Council (MRC) ConDuCT-II Hub (Collaboration and innovation
466 for Difficult and Complex randomised controlled Trials In Invasive procedures - MR/K025643/1)

467 [Authors' contributions:](#)

468 Mr Nigel J Hall, Chief Investigator

469 Miss Natalie Hutchings, Trial Manager

470 Dr Isabel Reading, Study Statistician

471 Dr Wendy Wood, Co applicant

472 Professor Bridget Young, Qualitative Sub Study lead

473 Dr Erin Walker, PPI lead and SSAG facilitator

474 Dr William Van't Hoff, Co applicant

475 Professor Jane Blazeby, Co applicant

476 Dr Esther Crawley, Co applicant

477 Dr Simon Eaton, COS Sub Study lead

478 Ms Maria Chorozioglou, Health Economist

479 Dr Frances Sherratt

480 Miss Lucy Beasant

481 Ms Harriet Corbett, Co-Investigator

482 Mr Michael Stanton, Co-Investigator

483 Mr Simon Grist, PPI Co applicant

484 Mrs Elizabeth Dixon, Senior Trial Manager

485 NH and NJH developed the first draft of the manuscript in accordance with the SPIRIT checklist [see

486 Additional file 2]. BY, FS and LB composed the Qualitative Sub Study section and EW drafted the PPI

487 section. All authors reviewed and approved the final manuscript.

488 [Acknowledgement:](#)

489 The authors would like to acknowledge the key role played by the following people:

490 - Sponsor, University Hospitals Southampton NHS Foundation Trust, R&D department, Southampton

491 General Hospital, Tremona Rd, SO16 6YD

492 - All PPI input, specifically our SSAG

- 494 1. St Peter, S.D., et al., *Single daily dosing ceftriaxone and metronidazole vs standard triple*
495 *antibiotic regimen for perforated appendicitis in children: a prospective randomized trial.* J
496 *Pediatr Surg*, 2008. **43**(6): p. 981-5.
- 497 2. Minneci, P.C., et al., *Effectiveness of Patient Choice in Nonoperative vs Surgical Management*
498 *of Pediatric Uncomplicated Acute Appendicitis.* *JAMA Surg*, 2015: p. 1-8.
- 499 3. Varadhan, K.K., K.R. Neal, and D.N. Lobo, *Safety and efficacy of antibiotics compared with*
500 *appendectomy for treatment of uncomplicated acute appendicitis: meta-analysis of*
501 *randomised controlled trials.* *BMJ : British Medical Journal*, 2012. **344**.
- 502 4. Lee, S.L., et al., *Does age affect the outcomes and management of pediatric appendicitis?* *J*
503 *Pediatr Surg*, 2011. **46**(12): p. 2342-5.
- 504 5. Mizrahi, I., et al., *Comparison of pediatric appendectomy outcomes between pediatric*
505 *surgeons and general surgery residents.* *J Surg Res*, 2013. **180**(2): p. 185-90.
- 506 6. Tiboni S, B.A., Hall NJ, *Outcome of appendectomy in children performed in paediatric*
507 *surgery units compared with general surgery units.* *Br J Surg*, 2014. **101**(6): p. 707-714.
- 508 7. Georgiou, R., et al., *Efficacy and Safety of Nonoperative Treatment for Acute Appendicitis: A*
509 *Meta-analysis.* *Pediatrics*, 2017. **139**(3).
- 510 8. Bowers, W.F., C.W. Hughes, and K.B. Bonilla, *The treatment of acute appendicitis under*
511 *suboptimal conditions.* *U S Armed Forces Med J*, 1958. **9**(11): p. 1545-57.
- 512 9. Vons, C., et al., *Amoxicillin plus clavulanic acid versus appendectomy for treatment of acute*
513 *uncomplicated appendicitis: an open-label, non-inferiority, randomised controlled trial.*
514 *Lancet*, 2011. **377**(9777): p. 1573-1579.
- 515 10. Styrud, J., et al., *Appendectomy versus antibiotic treatment in acute appendicitis. a*
516 *prospective multicenter randomized controlled trial.* *World J Surg*, 2006. **30**(6): p. 1033-1037.
- 517 11. Hansson, J., et al., *Randomized clinical trial of antibiotic therapy versus appendectomy as*
518 *primary treatment of acute appendicitis in unselected patients.* *Br J Surg*, 2009. **96**(5): p. 473-
519 481.
- 520 12. Eriksson, S. and L. Granstrom, *Randomized controlled trial of appendectomy versus*
521 *antibiotic therapy for acute appendicitis.* *Br J Surg*, 1995. **82**(2): p. 166-169.
- 522 13. Mason, R.J., *Surgery for appendicitis: is it necessary?* *Surg Infect (Larchmt)*, 2008. **9**(4): p.
523 481-8.
- 524 14. Ansaloni, L., et al., *Surgery versus conservative antibiotic treatment in acute appendicitis: a*
525 *systematic review and meta-analysis of randomized controlled trials.* *Dig Surg*, 2011. **28**(3): p.
526 210-21.
- 527 15. Liu, K. and L. Fogg, *Use of antibiotics alone for treatment of uncomplicated acute*
528 *appendicitis: a systematic review and meta-analysis.* *Surgery*, 2011. **150**(4): p. 673-683.
- 529 16. Minneci, P.C., et al., *Feasibility of a nonoperative management strategy for uncomplicated*
530 *acute appendicitis in children.* *J Am Coll Surg*, 2014. **219**(2): p. 272-9.
- 531 17. Gorter, R.R., et al., *Initial antibiotic treatment for acute simple appendicitis in children is safe:*
532 *Short-term results from a multicenter, prospective cohort study.* *Surgery*, 2015. **157**(5): p.
533 916-23.
- 534 18. Svensson, J.F., et al., *Nonoperative treatment with antibiotics versus surgery for acute*
535 *nonperforated appendicitis in children: a pilot randomized controlled trial.* *Ann Surg*, 2015.
536 **261**(1): p. 67-71.
- 537 19. Barsness, K.A., et al., *IL-1beta induces an exaggerated pro- and anti-inflammatory response*
538 *in peritoneal macrophages of children compared with adults.* *Pediatr Surg Int*, 2004. **20**(4): p.
539 238-42.
- 540 20. Barsness, K.A., et al., *Endotoxin induces an exaggerated interleukin-10 response in peritoneal*
541 *macrophages of children compared with adults.* *J Pediatr Surg*, 2004. **39**(6): p. 912-5;
542 discussion 912-5.

- 543 21. Dimmitt, R.A., et al., *Salvage laparotomy for failure of peritoneal drainage in necrotizing*
544 *enterocolitis in infants with extremely low birth weight*. J Pediatr Surg, 2000. **35**(6): p. 856-
545 859.
- 546 22. Abes, M., B. Petik, and S. Kazil, *Nonoperative treatment of acute appendicitis in children*. J
547 Pediatr Surg, 2007. **42**(8): p. 1439-42.
- 548 23. Armstrong, J., et al., *Non-operative management of early, acute appendicitis in children: is it*
549 *safe and effective?* J Pediatr Surg, 2014. **49**(5): p. 782-5.
- 550 24. Steiner, Z., et al., *A role for conservative antibiotic treatment in early appendicitis in children*.
551 J Pediatr Surg, 2015. **50**(9): p. 1566-8.
- 552 25. Turhan, A.N., et al., *Comparison of operative and non operative management of acute*
553 *appendicitis*. Ulus Travma Acil Cerrahi Derg, 2009. **15**(5): p. 459-62.
- 554 26. Hall, N.J., et al., *Appendectomy versus non-operative treatment for acute uncomplicated*
555 *appendicitis in children: study protocol for a multicentre, open-label, non-inferiority,*
556 *randomised controlled trial*. BMJ Paediatrics Open, 2017. **1**(1).
- 557 27. Xu, J., et al., *Acute uncomplicated appendicitis study: rationale and protocol for a*
558 *multicentre, prospective randomised controlled non-inferiority study to evaluate the safety*
559 *and effectiveness of non-operative management in children with acute uncomplicated*
560 *appendicitis*. BMJ Open, 2016. **6**(12): p. e013299.
- 561 28. Folaranmi, S.E., et al., *Variation in provision and outcome of emergency appendectomy in*
562 *paediatric specialist centres*. Bulletin of The Royal College of Surgeons of England, 2014.
563 **96**(10): p. 9-14.
- 564 29. Sherratt, F.C., et al., *Development of a core outcome set to determine the overall treatment*
565 *success of acute uncomplicated appendicitis in children: a study protocol*. BMJ Paediatrics
566 Open, 2017. **1**(1).
- 567 30. Mays, N. and C. Pope, *Qualitative research in health care. Assessing quality in qualitative*
568 *research*. BMJ, 2000. **320**(7226): p. 50-52.
- 569 31. Bhangu, A., *Safety of short, in-hospital delays before surgery for acute appendicitis:*
570 *multicentre cohort study, systematic review, and meta-analysis*. Ann Surg, 2014. **259**(5): p.
571 894-903.
- 572 32. Serres, S.K., et al., *Time to appendectomy and risk of complicated appendicitis and adverse*
573 *outcomes in children*. JAMA Pediatrics, 2017.
- 574 33. Ingraham, A.M., et al., *Effect of delay to operation on outcomes in adults with acute*
575 *appendicitis*. Arch Surg, 2010. **145**(9): p. 886-92.
- 576 34. Drake, F.T., et al., *Time to appendectomy and risk of perforation in acute appendicitis*. JAMA
577 Surg, 2014. **149**(8): p. 837-44.
- 578 35. Hornby, S.T., et al., *Delay to surgery does not influence the pathological outcome of acute*
579 *appendicitis*. Scand J Surg, 2014. **103**(1): p. 5-11.

580 [Additional files](#)

581 [Figure 1:](#)

582 Figure1.docx, Clinical pathway for both treatment arms

583 [Figure 2:](#)

584 Figure2.doc, Patient schedule of procedures (SPIRIT).

585 [Additional file 1:](#)

586 Additional file 1.doc, Parental Consent form with optional patient assent

587 [Additional file 2:](#)

588 Additional file 2.doc, SPIRIT Checklist